510(k) Report

510(k) · Cleared

Cleared

Unity Subcutaneous Infusion System for Remodulin

K191313510(k) TraditionalCleared Feb 21, 2020282-day reviewClass II21 CFR 880.5725

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

DEKA Research & Development · QJY Infusion Pump, Drug Specific, Pharmacy-Filled

Cleared on Feb 21, 2020 as substantially equivalent to K190182 (DEKA Research & Development, 2019) after a 282-day review. Its family tree reaches back 2 generations to 2005. 3 later devices descend from it.

Decided
Feb 21, 2020
Review
282 days
Class
Class II
Product code
QJY
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to K051568 (2005). 3 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2020: 1 descendant cleared2024: 2 descendants clearedK051568 · Cadd-MS 3 Ambulatory Infusion Pump · Smiths Medical MD, Inc. · 2005 · recalledK190182 · Unity Subcutaneous Delivery System for Remodulin · DEKA Research & Development · 201920052010201520202025
Descendants, by generation 1 generation forward: 2 descendants2 generations forward: 1 descendant K190182 · Unity Subcutaneous Delivery System for Remodulin · DEKA Research & Development · 2019K051568 · Cadd-MS 3 Ambulatory Infusion Pump · Smiths Medical MD, Inc. · 2005 · recalled0
  1. Root · 2 generations backK051568 Cadd-MS 3 Ambulatory Infusion PumpSmiths Medical MD, Inc. · 2005 · Recalled
  2. 1 generation backK190182 Unity Subcutaneous Delivery System for RemodulinDEKA Research & Development · 2019
  3. This deviceK191313 Unity Subcutaneous Infusion System for RemodulinDEKA Research & Development · 2020
  4. Descendant · cites it directly · 1 of its ownK202690 Remunity Pump for Remodulin (treprostinil) InjectionDeka Research and Development · 2020
  5. Descendant · cites it directly · 0 of its ownK243354 Remunity SystemDeka Research & Development Corp. · 2024
  6. Descendant · 2 generations on · 0 of its ownK240256 Remunity SystemDeka Research and Development · 2024

Most influential descendants

Showing 3 of 3 · See all
  • K202690Remunity Pump for Remodulin (treprostinil) InjectionDeka Research and Development · 2020 · cites it directly1descendant
  • K243354Remunity SystemDeka Research & Development Corp. · 2024 · cites it directly0descendants
  • K240256Remunity SystemDeka Research and Development · 2024 · 2 generations on0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K051568Cadd-MS 3 Ambulatory Infusion PumpSmiths Medical MD, Inc.20052
−1K190182Unity Subcutaneous Delivery System for RemodulinDEKA Research & Development2019—
0 (this device)K191313Unity Subcutaneous Infusion System for RemodulinDEKA Research & Development2020—
+1K202690Remunity Pump for Remodulin (treprostinil) InjectionDeka Research and Development2020—
+1K243354Remunity SystemDeka Research & Development Corp.2024—
+2K240256Remunity SystemDeka Research and Development2024—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202010
202420
FIG. 1 — Lineage of K191313, 2005–2024Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QJY? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QJY device

  1. #1 K243354 Remunity Systemscore 9.0 · 3 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K190182Unity Subcutaneous Delivery System for Remodulin
Summary page 4
…cy-filled Class: II Device Panel: General Hospital Predicate Device Unity Subcutaneous Delivery System for Remodulin® K190182. No reference devices are used in this submission. Device Description The Unity Subcutaneous Delivery System for Remodulin® (Uni…
DEKA Research & Development2019—

Also cleared against K190182: 1 other device →

What descends from it? (3)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K202690Remunity Pump for Remodulin (treprostinil) InjectionDeka Research and Development20201
K243354Remunity SystemDeka Research & Development Corp.20240

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 15 years and passes through 2 companies; a new generation was cleared every 13.5 years on median.
  • 1 of the 2 ancestors has a recall of any class.
  • Of its descendants, K202690 (Deka Research and Development, 2020) has gone furthest, with 1 descendant of its own.
  • 1 other device also cites its predicate K190182.

How does its category compare?

All QJY devices

QJY Infusion Pump, Drug Specific, Pharmacy-Filled: FDA decisions, review times, recalls and adverse event reports over 20 years. 2020, this device’s year, is highlighted.

FDA decisions per year · QJY

2in 2024

2020: 22024: 2
2007high 2 (2020) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QJY

Too few QJY 510(k)s in any year since 2007 to give a median.

Recalls per year · QJY

No recall names QJY since 2007.

Adverse event reports per year · QJY

154in 2025

2021: 42022: 222023: 612024: 432025: 154
2007high 154 (2025) · low 0 (2007)2025

MAUDE reports naming product code QJY, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20202—00
20210—04
20220—022
20230—061
20242—043
20250—0154
20260—0—

What is it indicated for?

The Unity Subcutaneous Infusion System (the Unity System) is intended for continuous subcutaneous delivery of

Remodulin® (treprostinil) Injection for use in adults (greater than 22 years of age).

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K191313: Unity Subcutaneous Infusion System for Remodulin.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K191313

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026